Gene Therapy Offers Transformative Hope for Thalassemia Patients in Abu Dhabi
A groundbreaking collaboration between Yas Clinic and Abu Dhabi Stem Cells Center has achieved remarkable results, liberating a patient from years of dependence on regular blood transfusions through advanced gene therapy treatment.
The convergence of medical innovation and clinical excellence has yielded an extraordinary advancement in the treatment of thalassemia within the Emirates. Yas Clinic, in partnership with Abu Dhabi Stem Cells Center, has successfully pioneered gene therapy treatments that address the underlying mechanisms of inherited blood disorders, offering patients a transformative alternative to traditional management approaches.
For decades, individuals living with transfusion-dependent thalassemia have endured the considerable burden of regular blood transfusions, typically required every three to four weeks to sustain adequate hemoglobin levels. Beyond the immediate demands of treatment, these patients contended with significant complications, including iron overload and the necessity for continuous iron chelation therapy, factors that profoundly constrained their quality of life and personal autonomy.
The innovative therapeutic approach represents a paradigm shift in addressing inherited blood disorders. Rather than relying upon external blood sources, the treatment utilises the patient’s own stem cells, which are meticulously genetically modified before reinfusion following preparatory therapy. This sophisticated technique shares conceptual similarities with autologous transplantation, yet addresses the fundamental genetic foundations of the disease itself.
The successful treatment of a 43-year-old patient demonstrates the remarkable potential of this advancement. Following comprehensive medical evaluations and extensive multidisciplinary assessments, the patient underwent gene therapy and has since achieved transfusion independence. The liberation from frequent hospital visits and the restoration of personal autonomy represent profound improvements in both physical health and overall wellbeing.
Dr. Maysoon Al Karam, Chief Medical Officer at Yas Clinic, observed that this achievement reflects the United Arab Emirates’ steadfast commitment to providing patients access to the most advanced therapeutic options available. She emphasised the clinic’s dedication to investing in medical innovation whilst ensuring that world-class care remains accessible within the nation’s healthcare landscape.
Dr. Mohammed Abu Haleeqa, Hematologist at Yas Clinic, articulated the profound significance of enabling patients to achieve independence from regular transfusions. For those who have devoted much of their lives to managing their condition through conventional means, the opportunity to address the disease’s fundamental cause represents a genuinely life-changing prospect. Gene therapy offers particular value to patients for whom suitable bone marrow donors may not be available, expanding therapeutic possibilities across the patient population.
This milestone underscores Abu Dhabi’s emerging position as a regional centre for advanced healthcare and medical innovation. The collaborative efforts of Yas Clinic and Abu Dhabi Stem Cells Center, supported by the Department of Health and the nation’s leadership, demonstrate an unwavering commitment to making cutting-edge treatments available to patients within the UAE, transforming lives through scientific advancement and clinical excellence.
Source: WAM